


# **EPIDEMIOLOGY OF ENTERIC (TYPHOID) FEVER AND PARATYPHOID FEVER-2023**



**Assistant prof.  
Dr. Alaa A. Salih  
FICMS/FM**

# CASE DEFINITION

## *Salmonella* Typhi infection

### Clinical for Public Health Surveillance:

One or more of the following:

- ❑ Fever
- ❑ Diarrhea
- ❑ Abdominal pain
- ❑ Constipation
- ❑ Anorexia
- ❑ Relative bradycardia.



# CASE DEFINITIONS AND FINAL CLASSIFICATION

---

## SUSPECTED CASE OF TYPHOID OR PARATYPHOID FEVER FOR CASE FINDING

- Fever for at least three out of seven consecutive days in an endemic area or following travel from an endemic area
- OR Fever for at least three out of seven consecutive days within 28 days of being in household contact with a confirmed case of typhoid or paratyphoid fever

## ❑ CONFIRMED CASES

Typhoid fever: Laboratory confirmation by

### ❑ **Culture**

❑ Molecular methods of *S. Typhi* or detection of *S. Typhi* DNA .



# Laboratory Criteria for Case Classification:

---

- ▣ *Confirmatory laboratory evidence:*

Isolation of *S. Typhi* from a clinical specimen.

- ▣ *Presumptive laboratory evidence:*

Detection of *S. Typhi* in a clinical specimen using a culture-independent diagnostic test (CIDT).

Note: Serologic testing should not be utilized for case classification. =Widal test

# Relapse of typhoid or paratyphoid fever:

---

- ❑ Laboratory confirmation of *S. Typhi* or *S. Paratyphi* from a normally sterile site within one month of completing an appropriate course of antimicrobial treatment and resolution of symptoms.

# CHRONIC CARRIERS TYPES

---

- ▣ Presumptive carrier:

Evidence of shedding of *Salmonella* spp.  
(positive stool culture or PCR) of an  
unknown duration.

# Definitive carrier

---

- Evidence of shedding of Salmonella spp. (positive stool culture or PCR) at least 12 months **after** finishing an appropriate course of antibiotics treatment .

OR » Two positive stool samples 12 months apart

# Convalescent carrier:

---

Evidence of shedding *Salmonella* spp.  
(positive stool culture or PCR)

**1–12 months** after finishing an appropriate course of antimicrobial treatment and the resolution of symptoms following a laboratory-confirmed episode of acute disease

# LABORATORY ANALYSIS

---

- ❑ There is no definitive test for typhoid or paratyphoid fever.
- ❑ The initial diagnosis is made clinically.
- ❑ Presentation is often confused with malaria,
- ❑ Typhoid fever and paratyphoid fever should be suspected in a person with a history of travel to an endemic who is not responding to antimalarial medication

# Testing currently available


---

- Blood culture: positive in approximately half the cases (multiple cultures may be required).
- Bone-marrow culture: increases the diagnostic yield to about 80% and is unaffected by prior or concurrent antibiotic use.
- Stool or Urine culture: Not usually, positive during the early acute phase of the disease (first week of illness) but is used to determine if a person is a typhoid carrier.
- Culture of bile (collected from a bile-stained duodenal string): used with blood culture resulting in 90% diagnostic yield in children with enteric fever.

- 
- Newer serologic assays are more sensitive and specific than the **Widal test** but are not an adequate substitute for blood, stool, or bone marrow **culture**.
    - Vi antibody: found to be very high in chronic *S. typhi* carriers and has been used as a screening technique to identify carriers among food handlers, **but stool cultures are necessary to remove food handling restrictions**.

# Widal test

**A serology test for antibodies to O and H antigens of *Salmonella*; unreliable but is used in developing countries because of its low cost.**



# EPIDEMIOLOGY

---

- ❑ Enteric fever has become rare in developed nations.
- ❑ however, there are an estimated 27 million cases of enteric fever, with 200,000–600,000 deaths annually

- 
- ❑ **The annual incidence is highest (>100 cases/100,000 population) in south-central and South east Asia**
  - ❑ **Medium (10–100 cases/100,000) in the rest of Asia, Africa, Latin America.**
  - ❑ **low in other parts of the world**



WHO Estimate

Infecteds roughly 21.6  
million people each  
year



WHO Estimate

Kills 216000-  
600000 people  
each year

# Iraq-Epidemiology

---

- Typhoid fever, a waterborne and foodborne disease, is **endemic** in Iraq.
- Hot weather and the frequent interruptions of electricity and water supply during the summer months have resulted in increased incidence.
- As a result, numerous interventions were implemented to prevent and control outbreaks.
- In 2007, 2008, 2009 and 2010, a total of 36 208, 58 247, 49 113 and 49 139 suspected cases of typhoid fever were reported, respectively.

# Risk factors

---

- ❑ contaminated water or ice
- ❑ Flood
- ❑ Food and drinks purchased from street
- ❑ Raw fruits and vegetables grown in Fields fertilized with sewage.
- ❑ Ill household contacts,
- ❑ lack of hand washing and toilet access,
- ❑ evidence of prior *Helicobacter pylori* infection (an association probably related to chronically reduced gastric acidity).

# Causative agent

---

- ❑ Typhoid is caused by *Salmonella typhi*.
- ❑ *It is readily killed* on heating to 60°C for 15 minutes or on boiling.
- ❑ It can survive in ice for considerable time and for some days in fresh or salt water. It can withstand drying, hence dust and dry excreta or soiled clothes also play a part in the spread.
- ❑ It survives very long in oysters and shellfish and can multiply freely in milk and butter without changing their taste or appearance.
- ❑ It can survive in ripened cheese and lives in sewage or sewage contaminated water for sufficient time.

# Transmission

---

- ❑ Most commonly, food-borne or waterborne transmission results from fecal contamination by ill
- ❑ asymptomatic chronic carriers.
- ❑ Sexual transmission .
- ❑ Health care workers occasionally acquire enteric fever after exposure to infected patients or during processing of clinical specimens and cultures.

## □ **Occurrence:-**

Worldwide.  
(multiple resistant  
strains in Asia and  
Middle East )



# Age group :

---


- ❑ Typhoid fever may occur at any age but it is considered to be a disease mainly **of children and young adults.**
- ❑ In endemic areas, the highest incidence seen in **children aged 5–19 years.**



# Gender and race :

---

- ▣ Typhoid fever cases are more commonly seen in males than in females.
- ▣ On the contrary, **females** have a special predilection to become **chronic carriers**.  
as hide the bacteria in gall bladder



# Socio-economic factors :

---

- ▣ It is a disease of poverty as it is often associated with inadequate sanitation facilities and unsafe water supplies.

# Environmental factors

---

- Though the cases are observed through out the year,
- The peak incidence of typhoid fever is reported during **July - September**.

# Social factors :

---

- ❑ pollution of drinking water supplies,
- ❑ open air defecation and urination
- ❑ low standards of food and personal hygiene, and health ignorance.

---

**Nutritional status** : Malnutrition may enhance the susceptibility to typhoid fever by altering the intestinal flora or other host defenses.

**Incubation period** : Usually 8-14 days but it may be as short as 3 days or as long as 21 days depending upon the dose of the inoculums.

- 
- ❑ **Reservoir of infection** : Man is the only known reservoir of infection - cases or carriers.
  - ❑ **Period of communicability**: A case is infectious as long as the bacilli pass in stool or urine.
  - ❑ About 10% of untreated typhoid fever patients discharge bacilli for 3 months after onset of symptoms.
  - ❑ 2%–5% become permanent carriers.

# TIPS

---

- ❑ A person should be declared non infective only when three weekly stool cultures are negative.
- ❑ Fecal carriers excrete around 10<sup>11</sup> organisms per gram of stool.
- ❑ Female carriers are **three times** more common than male carriers.

- 
- ❑ Anatomical abnormalities in biliary tract favor the carrier state.
  - ❑ Gallstones are particularly favorable sites for salmonellae to reside.
  - ❑ The organisms can easily go in and out of the stones.
  - ❑ Organisms in the gallbladder are not affected by Chloramphenicol even in inhibitory concentrations.

---

# TREATMENT

# Management: Antibiotics

- Antibiotic Resistance is increasing  
( to Fluoroquinolone )
- Infection acquired outside Asia
  - Ciprofloxacin :(500 mg orally) every 12 hours for 7-10 days
  - Levofloxacin ( 750 mg orally) every 24 hours for 7-10 days



# Management: Antibiotics

- **Infection acquired in Asia**


- Ceftriaxone 1 g IV/IM every 12 hours for 7-14 days OR
- Azithromycin 1 g orally day 1, then 500 mg orally daily for 5-7 days
  - Consider using Azithromycin combined WITH Ceftriaxone in ill hospitalized patients

- **Alternative antibiotics (resistance is common)**

- Chloramphenicol 500 mg IV or oral every 6 hours for 14 days

- **Additional measures**

- Consider adding Dexamethasone in seriously ill patients



# Control of Typhoid fever

---

## **MEASURES DIRECTED TO RESERVOIR**

- a) Case detection and treatment**
- b) Isolation**
- c) Disinfection of stools and urine**
- d) Detection & treatment of carriers**

## **MEASURES AT ROUTES OF TRANSMISSION**

- a) Water sanitation**
- b) Food sanitation**
- c) Excreta disposal**
- d) Fly control**

## **MEASURES FOR SUSCEPTIBLES**

- a) immunoprophylaxis**
- b) health education**

# TYPHOID VACCINES




# Typhoid conjugate vaccine (TCV)

- **WHO recommends the introduction of typhoid conjugate vaccine-2018 (TCV) for infants and children over six months of age in typhoid-endemic countries**
- **The vaccine has long-lasting immunity, requires only one dose .**



# Injectable Typhim -Vi

1. This single-dose injectable typhoid vaccine, from the bacterial capsule of *S. typhi* strain of Vi CPS. with a booster every 2 years
2. This vaccine is recommended for use in children over 2 years of age.
3. Sub-cutaneous or intramuscular injection
4. Efficacy : 64% -72%



# Typhoral=Ty21a

1. This is a **live-attenuated-bacteria vaccine** .
2. The efficacy rate of the oral typhoid vaccine ranges from **50-80%**
3. *Not* recommended for use in children younger than **6 years of age**.
4. The course consists of one capsule orally, taken an hour before food with a glass of water or milk on alternating days, as 4 capsules
5. No antibiotic should be taken during this period
6. Immunity starts **2-3 weeks** after administration and lasts for **3 years**
7. A booster dose after **3 years**

**Ty21a**—Oral live attenuated vaccine

# REMEMBER

## Oral Typhoid Fever Vaccine

DAY

1



DAY 2  
SKIP

DAY

3



DAY 4  
SKIP

DAY

5



DAY 6  
SKIP

DAY

7



9/9

9/11

9/13

9/15

**Vivotif®**

Typhoid Vaccine Live Oral Ty21a

800-533-5899

Berna  
Products

Orion Vaccines Inc.

>B-

## Indications for Vaccination

---

1. Travelers going to endemic areas who will be staying for a prolonged period of time,
2. Persons with intimate exposure to a documented *S. typhi* carrier
3. Microbiology laboratory technologists who work frequently with *S. typhi*
4. Immigrants
5. Military personnel

# The following recommendations will help ensure safety while travelling

---

- ❑ Ensure food is properly cooked and still hot when served.
- ❑ Avoid raw milk and products made from raw milk. Drink only pasteurized or boiled milk.
- ❑ Avoid ice unless it is made from safe water.
- ❑ When the safety of drinking water is questionable, boil it or if this is not possible, disinfect it with a reliable, slow-release disinfectant agent (usually available at pharmacies).
- ❑ Wash hands thoroughly and frequently using soap, in particular after contact with pets or farm animals, or after having been to the toilet.
- ❑ Wash fruits and vegetables carefully, particularly if they are eaten raw. If possible, vegetables and fruits should be peeled.



# References

---

- Typhoid Fever & Paratyphoid Fever (*Salmonella* serotype Typhi and *Salmonella* serotype Paratyphi) 2021
- [Control of Communicable Diseases Manual, 21st Edition](#)
- 21st Edition\***HARRISON'S** PRINCIPLE OF INTERNAL MEDICINE
- [https://cdn.who.int/media/docs/default-source/immunization/vpd\\_surveillance/vpd-surveillance-standards-publication/who-surveillancevaccinepreventable-21-typhoid-r2.pdf?sfvrsn=993904a6\\_10&download=true](https://cdn.who.int/media/docs/default-source/immunization/vpd_surveillance/vpd-surveillance-standards-publication/who-surveillancevaccinepreventable-21-typhoid-r2.pdf?sfvrsn=993904a6_10&download=true)

# THANK YOU

